LB Bohle – 10.06.2025
Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025
Stoelzle – 15th May 2025

Batavia Biosciences Expands its Viral Vector and GMP Facilities to Accommodate Increasing Market Demand

Today, Batavia Biosciences announces the expansion of its viral vector process development facilities in the USA and its GMP clean room facilities in the Netherlands to accommodate the increasing market demand.
Chris Yallop, CSO Batavia Biosciences, explains: “Recent advances in cancer vaccines and gene therapy have given rise to a profound increase in the global demand for process development and clinical manufacturing of vector based products.”
The R&D facility in Medford, located just north of Cambridge (MA) allows Batavia Biosciences to extent the existing service portfolio in the United States, adding complete pre-clinical process development capabilities for viral vectors including AAV, Lentivirus, VSV and Adenovirus systems to its portfolio of CHO cell line generation and process development services for recombinant proteins and antibodies.
Expansion of its GMP clean room facilities in Leiden, the Netherlands better aligns the company’s GMP capacity with its increased R&D capability to further support the manufacturing of master cell banks and vaccine seed stocks.
Menzo Havenga, CEO Batavia Biosciences, concludes: “At Batavia Biosciences we are very much aware of the fact that the patient is waiting. With the completion of this investment, the company is now better positioned to maintain the speed and quality of bringing candidate biopharmaceuticals from bench to clinic.”

Scott Pharma – 25.03.2025
Bespak – 21.05.2025
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
Nipro – 09.06.2025
L.B. Bohle – 08.04.2025
Drug Discovery 2025, ELRIG – 04.07.2025